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Abstract
Mutations in the isocitrate dehydrogenase (IDH) genes are frequently found in gliomas and in a fraction of acute myeloid
leukemia patients. This results in the production of an oncometabolite, 2-hydroxyglutarate (2-HG). Glioma patients
harboring IDH mutations have a longer survival than their wild-type counterparts. 2-HG has been detected non-
invasively in gliomas with IDH mutations using magnetic resonance spectroscopy (MRS), suggesting its potential
clinical relevance for identifying glioma subtypes with better prognosis. In this paper, the recent developments in
the MRS detection of the 2-HG in gliomas are reviewed, including the therapeutic potentials and translational values.
Translational Oncology (2013) 6, 92–98
Introduction
Somatic mutations in the genes isocitrate dehydrogenase 1 (IDH1) and
IDH2 have been identified in a subset of gliomas, acute myeloid leuke-
mia, and less frequently in other malignancies [1–4]. These mutations
result in the substitution of the arginine 132 (in IDH1) and arginine
172 (in IDH2) codons by histidine, causing alterations in the normal
enzymatic activities of IDH1-R132 and IDH2-R172 [1]. IDH muta-
tions are associated with alterations in DNA methylation and impede
the oxidative decarboxylation of isocitrate, resulting in overproduction
and accumulation of the oncometabolite 2-hydroxyglutarate (2-HG)
instead of α-ketoglutarate [1,5,6].
Being a direct and noninvasively detectable metabolic consequence
of a genetic mutation in cancer, 2-HG detection in glioma serves as a
unique biomarker for identifying IDH mutations. The potential diag-
nostic value of 2-HG as a biomarker of patient survival is further con-
firmed by better survival in patients with IDH mutations than wild
type. IDH mutations have been reported in more than 70% of low-
grade gliomas [World Health Organization (WHO) grades II and
III] and secondary glioblastomas (Table 1), while the frequency of
IDH mutations in primary glioblastoma is much lower (<10%)
[3,7,8]. Secondary glioblastomas may often be incorrectly diagnosed
as primary glioblastomas [9]. Hence, the detection of 2-HG could be
a potential tool for in vivo distinction of secondary from primary glio-
blastomas [10]. The molecular pathogenesis of IDH1/2 mutations in
the development of gliomas has yet to be identified. However, such
identification may improve our understanding of the mechanisms of
glioma development and may lead to the development of novel molec-
ular classification and therapy. 2-HG being a magnetic resonance
(MR)–visible indicator of IDH mutation offers unique possibilities in
monitoring and tracking glioma patients.
Both IDH1 and IDH2 are NADP+-dependent (oxidized form of
nicotinamide adenine dinucleotide phosphate) enzymes catalyzing
the conversion of isocitrate to α-ketoglutarate (Figure 1). In mutant
tumors, the NADPH levels are decreased, causing a potential effect
in cellular biosynthetic processes, such as lipogenesis [2]. By metabolic
profiling, more than 200 metabolites have been analyzed in human
oligodendroglioma cells engineered to express mutant IDH1/IDH2
[11]. The major biologic alterations identified were increased levels
of free amino acids and lipid precursors and depletion of metabolites
involved in the tricarboxylic acid cycle (also known as Krebs cycle):
citrate, α-ketoglutarate, fumarate, cis-aconitate, and malate [11].
MR spectroscopy (MRS) has been widely used as a quantitative
analytical tool for monitoring metabolism in different types of malig-
nancies [12,13]. Metabolic profiling helps in assessing pathophysio-
logical processes associated with tumor biology and is a valuable
monitoring tool for developing novel therapeutic anticancer agents
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[12]. More recently, promising results have been obtained using this
technique for 2-HG detection in vivo [14,15]. Crucial to these
approaches were the determination of whether the accumulation of
2-HG in IDH-mutated gliomas was within the range ofMRS-detectable
levels and in the precise assignment of 2-HG resonances overlapping
with other metabolites using conventional one-dimensional (1D)
MRS. This mini-review highlights the recent developments in the
detection of the 2-HG metabolite in gliomas using MRS, including
the therapeutic potentials of targeting IDH mutant cells. The potential
translational values of MRS-based IDH detection and future directions
are discussed.
MRS Principles
MRS can map metabolic profiles and dynamics in vivo or within tissue
extracts or intact tissue samples in a laboratory setting. MRS detects
MR signals from stimulated nuclear spins in a strong static magnetic
field. When placed in an external strong magnetic field (B0), atomic
nuclei with a magnetic dipole moment (such as 1H, 13C, or 31P) precess
around B0 at specific frequencies. By applying an excitation radio-
frequency (RF) pulse at resonance with this precession, nuclei can be
brought to a higher energy state. Following the excitation, the nuclei
recover to the equilibrium state and the absorbed energies are released,
emitting RF signals. The RF receiver coils are tuned to detect only
the RF signals originating from the excited nuclei. Different nuclei
of the same type, e.g., 1H, experience slightly different magnetic
fields with respect to their molecular environment and therefore pre-
cess at slightly different frequencies. The frequency of detected sig-
nals is described on a field-independent dimensionless scale called
chemical shift (δ), which is expressed in parts per million (ppm; see
[16]). Individual molecular properties will be characterized by a single
resonance (e.g., N -acetylaspartic acid) or multiple resonances (e.g.,
lactate, a doublet resonance) in the MR spectra (Figure 2A). The signal
intensity reflects the number of excited nuclei in the molecule. The
MRS technique enables detection of a wide array of metabolites simul-
taneously. In this review, we refer to studies observing the nucleus of
the hydrogen atom (proton, 1H), which is most commonly used in
MRS due to its high intrinsic sensitivity.
Ex Vivo MRS of Biopsy Specimens
High-resolution magic angle spinning (HRMAS) is a relatively
new solid-state MRS technique for metabolic profiling of intact tissue
samples. In solid state, molecules experience significant motion restric-
tion. The major reasons are molecular dipole-dipole interactions and
chemical shift anisotropy, resulting in spectral broadening with an
angular dependency. By rapidly spinning (typically 5000 Hz) the sam-
ple at an angle (θ = 54.7°) to the main magnetic field, the so-called
“magic angle,” the line broadening is markedly reduced, and the tissue
samples thus resemble a semiliquid phase [17]. The sample preparation
Table 1. Frequency of IDH Mutations in Various Glial Brain Tumors.
WHO Grade Glioma Type n IDH Mutation Status References
IDH1 IDH2 Combined (%)
II A 405 282 4 74 [3,4,6,7,24,35]
OA 196 150 1
O 363 268 8
III A 398 257 4 76 [3,4,6,7,24,35]
OA 279 229 11
O 245 184 12
IV GBM secondary 85 69 0 82 [3,6,7,9]
IV GBM primary 673 32 0 5 [3,6,7,9]
Abbreviations: A, astrocytoma; OA, oligoastrocytoma; O, oligodendroglioma.
Figure 1. Mutant IDH1/2 causes accumulation of the oncometabolite 2-HG. Metabolic pathway of 2-HG production follows the catalytic
reduction of α-ketoglutarate by IDH1 (cytoplasmic) and IDH2 (mitochondrial) through the conversion of NADPH to NADP+.
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Figure 2. 2-HG detection in IDH mutant gliomas and its MRS signature in 1H MR spectra. (A) Representative in vivo 1H MR spectra from
normal brain and gliomas. Single voxel (2 × 2 × 2 cm3)–localized PRESS spectra at 3 T together with spectral fits to the components of
2-HG, γ-aminobutyric acid, glutamate, and glutamine are shown. Vertical lines are drawn at 2.25 ppm to indicate the Hβ multiplet of 2-HG
in the PRESS-edited spectra. (B) HRMAS spectra from surgical specimens ex vivo obtained from glioma sample of WHO grade III astro-
cytoma; blue and red traces represent the acquired and fitted spectra, respectively. (C) A 2D spectrum acquired from the same tissue
sample representing the resonance cross-peaks about the F1/F2 diagonal. Three well-resolved proton resonances of 2-HG are located
along a vertical column (cross-peaks of 2-HGα, 2-HGβ, and 2-HGγ) at F2 = 4.05/F1 = 1.85 ppm, 4.05/2.01 ppm, and 4.05/2.28 ppm.
Adapted with permission from [14,27].
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is simple and straightforward. It typically includes weighing the samples
(approximately 5–30 mg), thawing them on an ice bed, and cutting
tissue samples either for direct loading into the MAS zirconium rotors
(small holders with air turbine to spin the sample) or for loading into
disposable inserts fitting the MAS rotors. A small amount of suitable
buffer (<5 μl) is used for chemical shift referencing and field locking
[18,19]. HRMAS is nondestructive, enabling subsequent biologic
evaluations such as histopathology or gene expression profiling in the
same tissue sample. This technique is well suited for the examination of
unprocessed surgical specimens ex vivo in a laboratory setting and has
the potential to be implemented in clinical workflows.
In Vivo MRS
When used in vivo, spatially localized MRS or MR spectroscopic
imaging is combined with conventional MR imaging to allow the
investigation of metabolic distribution within determined anatomic
regions. The MR spectra obtained using clinical scanners suffer from
poorer signal-to-noise ratio and spectral resolution compared to ex vivo
MRS. However, recent advances in MR technology, including access
to higher magnetic field strengths, have boosted the clinical potential
of in vivo MRS. In vivo MRS detection of 2-HG in IDH-mutated
glioma patients holds promise for reliable identification of this metab-
olite. Using a common spectroscopy sequence and field strength of 3 T
[14], which is commonly used in the clinical setting, the 2-HG reso-
nances have been identified without need for more specialized instru-
mentations. The data acquisition and post-processing methods used
in these studies could be also implemented on standard hardware
already in place in many MR imaging centers. Thus, the significance
of 2-HG detection could be assessed with well-defined clinical set-
tings and larger cohorts.
Detection of 2-HG by MRS
Detection of the 2-HG Metabolite Ex Vivo
HRMAS MRS provides a vast amount of biochemical information
from intact tissue samples with minimal sample preparation [18,20].
Many studies have demonstrated the ability of this method to inves-
tigate and quantify malignancy-associated metabolites in diagnosis,
prognosis, and treatmentmonitoring in cancer [21–25]. UsingHRMAS
MRS, the oncometabolite 2-HG has been detected in tissue specimens
resected from glioma patients harboring IDH1/IDH2mutations ex vivo
[26–28]. The MR signal arising from the 2-HG metabolite exhibits
complex features and overlaps with neighborhood resonances, such as
myo-inositol, glutamine, glutamate, and γ-aminobutyric acid (Fig-
ure 2B). By using two-dimensional (2D) correlation spectroscopy
(COSY) [29], the distinctive metabolite cross-peak pattern from the
proton correlations in a molecule can be distinguished (Figure 2C).
In a study by Elkhaled et al. [27], there was a significant correla-
tion between the presence of 2-HG as determined by MRS and
IDH1 mutation status as determined by IDH1-R132H immuno-
staining and direct genetic sequencing of IDH1. The authors found
a strong correlation between 2-HG levels and the presence of IDH
mutation. They also correlated the 2-HG levels with histopathologic
parameters, including cell density in tumor. Kalinina et al. [28]
investigated whether the presence of 2-HG in glioma cohorts was
reflected as a consequence of IDH1/IDH2 mutations across the sub-
types and grades including nontumorous controls. Beyond the com-
plexity, the 2D MR spectra clearly demonstrated the resolved proton
resonances of 2-HG. High sensitivity, specificity, and accuracy
(>95%) for the MRS-based identification of IDH1/IDH2 mutant
gliomas with high levels of 2-HG were obtained.
In Vivo MRS of Glioma Patients
The feasibility of using 2-HG as a biomarker of IDH mutation in
gliomas has been further established in vivo by using both 1D spec-
tral editing and 2D MRS techniques [14,15]. Using an edited point
resolved spectroscopy sequence (PRESS) [30], Choi et al. [14] iden-
tified the 2-HG resonances in 1H MR spectra of IDH-mutated gli-
omas at clinical field strength (3 T; Figure 2A). In an investigation of
glioma patients harboring IDH1 mutations, primary glioblastoma
multiforme (GBM) patients lacking IDH mutations, and healthy
volunteers, Andronesi et al. [15] found a correlation between the 2-HG
accumulation and IDH-mutated gliomas (Figure 3). Among 30 patients,
the 2-HG resonances were detected only in the 1H MR spectra of
IDH1-mutated gliomas, not in the GBM and healthy control cohorts,
confirming the high specificity [23] of the method. The feasibility of
detecting 2-HG using a localized 2D MRS sequence [31] using a 3-T
clinical scanner was also proven [15]. The 2-HG metabolites were also
assigned in the 1H MR spectra using localized 1D MRS.
Pope et al. [32] found the presence of 2-HG (with a sensitivity of
100%) in low-grade and recurrent GBM with IDH1 mutation. A
conventional single-voxel MRS sequence was used in this study,
showing the feasibility of detecting 2-HG resonances with current
clinical uses. Analyzing the MR spectra obtained from two cohorts
of patients, they found a significantly higher 2-HG level in mutant
IDH1 genotypes than in wild type. The metabolite peaks were fitted
using the LC Model software package [33] for estimating the metab-
olite level of 2-HG. When the glutamine and glutamate levels were
compared ex vivo, no significant differences were found between
wild-type and IDH1 mutant subgroups. Thus, the 2-HG peaks con-
tributed predominantly to the increases in the detected MRS signals
in vivo of glutamate + glutamine + 2-HG based on the LC Model
measurements [32]. However, the in vivo assignment of 2-HG reso-
nances is an important technical challenge because of the complex
spin-coupling features. This could lead to false-positive 2-HG detec-
tion in wild-type cohorts [32]. The MRS sequences may still need
further optimization and refinement to achieve reproducible sensitivity
and specificity applicable in clinical settings. In addition, it is important
to validate in vivo proof-of-principle data by implementing the proto-
cols in a larger cohort.
One of the challenges in studying the underlying biology of IDH
mutant gliomas in vivo could be the lack of reliable preclinical models
that can also be used to develop novel therapeutic strategies targeting
the IDHmutant cells. For this purpose, Luchman et al. [34] established
an orthotopic anaplastic oligoastrocytoma xenograft model with endog-
enous IDH1 mutations.
Clinical Perspective
More than 70% of low-grade glioma patients (grade II or III) carry
IDH1/IDH2 mutations. Most of the grade II and III gliomas prog-
ress over time to glioblastomas and are called secondary glioblas-
tomas. The frequency of IDH mutations is high (>70%) among
secondary glioblastomas compared to primary glioblastomas (<10%).
(Table 1). Thus, 2-HG may potentially distinguish primary glioblas-
tomas from secondary glioblastomas [10,35,36]. Moreover, IDH
mutations provide overall survival prediction, irrespective of glioma
grade. A better prognosis has been generally reported in glioma patients
carrying an IDH mutation [37,38]. Furthermore, a reduction in cell
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Figure 3. In vivo 2D MRS spectra of human brain subjects acquired at 3 T. Single voxels (red rectangles, 3 × 3 × 3 cm3) are placed on
the basis of fluid attenuated inversion recovery images prescribing abnormalities in tumor patients (left column), and the corresponding
metabolite cross-peak are depicted as contour maps (right column). (A) Astrocytoma patient with IDH1-R132C; the Hα-Hβ cross-peak of
2-HG located at 4.02/1.91 ppm (δ2/δ1). The 2D spectra acquired (voxel size of 3.5 × 3.5 × 3.5 cm
3) from a primary glioblastoma patient
with wt-IDH1 (B) and healthy volunteer with wt-IDH1 (C) do not contain any 2-HG cross-peak (outlined by the green rectangle). All 2D
spectra were acquired using a developed 2D localized adiabatic selective refocusing–COSY sequence with a repetition time of 45 milli-
seconds, 64 increments in F1 direction, 8 averages per F1 transient, and a total acquisition time of 12.8 minutes. Adiabatic pulses
improve the sequence performance by providing sharp and uniform excitation slices and a robust flip angle and by significantly decreasing
the chemical shift displacement error (see [31]). Adapted with permission from [15].
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proliferation, as a result of 2-HG accumulation in glioma cell lines, and
prolonged survival in mice injected with IDH1-R132H mutant cells
have been found [39]. Bralten et al. concluded that IDH1-R132H
mutations in gliomas are associated with better prognosis and reduced
aggressiveness, regarding both in vitro and in vivo results. Translating
noninvasive detection of 2-HG by MRS to clinical applications may
have a favorable impact on diagnosis, prognosis, treatment stratifica-
tion, and management of glioma patients.
Summary and Conclusion
Using MRS, the oncometabolite 2-HG can be detected with high
sensitivity (>90%) and specificity in gliomas harboring IDH muta-
tions ex vivo and in vivo. The capability of this technique in tracking
a mutation event suggests that 2-HG is a clinical valuable biomarker.
Thus, it may potentially help to investigate how the IDH mutation
accompanies gliomagenesis. Ex vivo analysis using HRMAS MRS
provides a nondestructive and highly sensitive method in which tis-
sue samples can be used for further histopathology and genomic anal-
yses, aiding a better understanding of tumor biology. In vivo studies
demonstrated the feasibility of detecting 2-HG noninvasively using
current clinical scanners. Further validation in larger cohorts may
improve the molecular characterization of IDH-mutant tumors. In con-
clusion, MRS is a useful and promising method for analyzing cancer-
associated metabolic alteration, providing mechanistic insights into
tumorigenesis, and presents a potential for therapeutic intervention.
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